CT 707Alternative Names: CT-707
Latest Information Update: 18 Mar 2016
At a glance
- Originator Beijing Sailin Tai Pharmaceutical; Centaurus Biopharma
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion kinase 1 inhibitors; Insulin-like growth factor-I receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 08 Mar 2016 Phase-I clinical trials in Non-small cell lung cancer in China (unspecified route)